Nicotine deprivation attenuates panic reactivity in smokers: Findings from a placebo-controlled nicotine patch study

What Was Tested

This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).

Prospective studies consistently find that smoking is a risk factor for the development of panic disorder (PD).

A possible explanation is that nicotine deprivation promotes heightened sensitivity to bodily sensations and/or arterial carbon dioxide (CO2 ).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Participants abstained from nicotine for 2 hr prior to sessions.

For both sessions, after a 3-hr absorption period, participants underwent a 10-min CO2 rebreathing challenge.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Moderate to heavy smokers without PD (N = 25) participated in a placebo-controlled, double-blind study consisting of two sessions spaced 1 week apart.

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Arousal, Culture, Fear, Nicotine, Panic Disorder and Risk Factors.

The authors tagged it with the keywords addiction, anxiety/anxiety disorders, panic attacks/agoraphobia, smoking and substance use disorders.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Depression and anxiety), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.